Zymeworks Shares Rise Ahead of FDA Decision on Zanidatamab
Zymeworks (NASDAQ:ZYME) shares rose nearly 4.0% in pre-market trading as investors anticipated a key U.S. Food and Drug Administration decision on zanidatamab, expected August 25, 2026. The FDA is reviewing the bispecific HER2-targeting antibody for first-line treatment of HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. A positive approval would trigger a $250 million U.S. regulatory milestone payment and potentially up to an additional $190 million in other markets, making the decision a significant financial catalyst for Zymeworks. Analysts from Citi, Truist, and Wells Fargo have highlighted the FDA ruling as a major near-term event, with some raising their price targets ahead of the PDUFA date. Zymeworks is also preparing to acquire Theravance Biopharma in an all-cash deal valued at $929 million. The acquisition would provide access to commercial cash flows from COPD treatment YUPELRI and diversify Zymeworks' revenue base as it advances its oncology pipeline.
Topics: biotech drug approval stock movement